Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia
Status:
Recruiting
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
With the introduction of all-trans-retinoic acid (ATRA) and arsenic,the outcome of patients
with acute promyelocytic leukemia (APL)has been improved considerably over the last
decades.However，early deaths (EDs), mainly due to APL-specific coagulopathy, differentiation
syndrome (DS)emerge as a major threat to APL patients.We observe and evaluate the effectivity
of induction therapy in patients with APL. Administrate intravenous dexamethasone to prevent
or preemptive treat DS. Assess the efficacy and safety of ruxolitinib as second treatment in
patients with severe DS with no respond to dexamethasone.Furthermore，the changes of spectrum
of cytokines are monitered to find the relationship between the cytokines and the severity of
DS.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University